COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss

BACKGROUND: Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common mechanism, involving reactive oxygen species in the inner ear. Aspirin has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Crabb, Simon J., Martin, Karen, Abab, Julia, Ratcliffe, Ian, Thornton, Roger, Lineton, Ben, Ellis, Mary, Moody, Ronald, Stanton, Louise, Galanopoulou, Angeliki, Maishman, Tom, Geldart, Thomas, Bayne, Mike, Davies, Joe, Lamb, Carolynn, Popat, Sanjay, Joffe, Johnathan K., Nutting, Chris, Chester, John, Hartley, Andrew, Thomas, Gareth, Ottensmeier, Christian, Huddart, Robert, King, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729023/
https://www.ncbi.nlm.nih.gov/pubmed/29128692
http://dx.doi.org/10.1016/j.ejca.2017.09.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729023/
https://www.ncbi.nlm.nih.gov/pubmed/29128692
http://dx.doi.org/10.1016/j.ejca.2017.09.033

Ejemplares similares